Physician profile
Rakesh Rohatgi
NPI 1750383980
$22,625.74
in general payments reported to CMS, 2019-2025
81 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,023 · 2020: $836 · 2021: $1,550 · 2022: $3,512 · 2023: $3,415 · 2024: $4,982 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $1,280 · Education: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,000.45 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $424.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,639.71 | 2019-2025 | |
| Dova Pharmaceuticals | $1,868.80 | 2019 | |
| Pfizer INC. | $1,195.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,145.69 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $1,137.25 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $1,068.60 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $937.33 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $916.92 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $851.28 | 2019-2025 | |
| Seagen INC. | $844.29 | 2019-2025 | Adcetris, Tukysa, Tivdak |
| Astellas Pharma US INC | $795.13 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Celgene Corporation | $794.44 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $686.75 | 2019-2025 | |
| Daiichi Sankyo INC. | $671.46 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Genentech USA, INC. | $414.92 | 2019-2025 | Tecentriq, Polivy, Perjeta |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.14 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $362.60 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Gilead Sciences, INC. | $347.91 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $314.56 | 2019-2024 | Jaypirca, Retevmo, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $289.63 | 2019-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $282.58 | 2019-2025 | Libtayo |
| Abbvie INC. | $274.17 | 2023-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $270.69 | 2019-2025 | |
| Array Biopharma INC | $258.57 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $245.50 | 2019-2025 | Bavencio |
| Kite Pharma, INC. | $240.61 | 2021-2024 | Yescarta |
| Jazz Pharmaceuticals INC. | $214.71 | 2019-2025 | Zepzelca |
| Alexion Pharmaceuticals, INC. | $192.55 | 2022-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $172.74 | 2020-2025 | Ojjaara, Blenrep |
| Taiho Oncology, INC. | $168.53 | 2019-2024 | |
| Servier Pharmaceuticals LLC | $145.80 | 2021-2025 | |
| Beigene USA, INC. | $135.57 | 2021-2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $133.37 | 2019-2025 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.75 | 2019-2024 | |
| Pharmaessentia USA Corporation | $100.60 | 2023-2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $98.28 | 2022-2025 | Fotivda |
| Stemline Therapeutics INC. | $96.18 | 2023-2025 | Orserdu |
| Sobi, INC | $93.19 | 2022-2024 | |
| Puma Biotechnology, INC. | $86.30 | 2021-2025 | |
| Octapharma USA, INC. | $82.73 | 2021 | |
| G1 Therapeutics, INC. | $81.65 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $80.10 | 2024 | Cosela, Monoferric |
| Myriad Genetic Laboratories, INC. | $75.64 | 2021-2024 | Precisetumor, Myrisk |
| Mirati Therapeutics, INC. | $74.50 | 2023-2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $65.39 | 2023 | Rolvedon |
| Genmab U.S., INC. | $60.92 | 2023-2025 | Epkinly |
| Adc Therapeutics America, INC. | $59.00 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $52.83 | 2019-2024 | Rezlidhia, Tavalisse |
| Beone Medicines USA, INC. | $52.80 | 2025 | Brukinsa |
| Kub Technologies INC. | $52.38 | 2024 | |
| Geron Corporation | $47.89 | 2025 | Rytelo |
| Cti Biopharma Corp. | $45.83 | 2023 | Vonjo |
| Clovis Oncology, INC. | $45.80 | 2019 | |
| Heron Therapeutics, INC. | $44.52 | 2019-2021 | |
| Acrotech Biopharma INC. | $43.61 | 2024 | Beleodaq |
| Secura Bio, INC. | $39.82 | 2022-2025 | Copiktra |
| Janssen Pharmaceuticals, INC | $39.69 | 2019-2020 | |
| Tesaro, INC. | $35.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.35 | 2019-2020 | |
| Foundation Medicine, INC. | $33.69 | 2020 | |
| Csl Behring | $32.08 | 2023 | Kcentra |
| Iovance Biotherapeutics, INC. | $31.41 | 2025 | Amtagvi |
| Tersera Therapeutics LLC | $30.69 | 2023 | Quzyttir |
| Blueprint Medicines Corporation | $29.01 | 2025 | Ayvakit |
| Alnylam Pharmaceuticals INC. | $26.26 | 2025 | Givlaari |
| Immunogen, INC. | $24.97 | 2023 | Elahere |
| Aurobindo Pharma USA, INC. | $24.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.00 | 2021 | |
| Tolmar, INC. | $23.02 | 2024 | |
| Amag Pharmaceuticals, INC. | $22.46 | 2021 | |
| Recordati_rare_diseases_inc. | $22.38 | 2025 | Enjaymo |
| Morphosys, US INC. | $21.83 | 2023 | Monjuvi |
| Exelixis INC. | $19.51 | 2025 | Cabometyx |
| Menarini Silicon Biosystems, INC. | $18.47 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $17.38 | 2019 | |
| Syndax Pharmaceuticals, INC. | $17.29 | 2025 | |
| Karyopharm Therapeutics INC. | $15.37 | 2023 | Xpovio |
| Kyowa Kirin, INC. | $14.43 | 2021 | |
| Eusa Pharma (US) LLC | $13.18 | 2019 | |
| Verastem, INC. | $13.18 | 2019 | |
| Global Blood Therapeutics, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
Kisqali $1,461Keytruda $422Lenvima $376Imfinzi $338Opdivo $333Xtandi $325Reblozyl $318Sarclisa $317Tukysa $285Monjuvi $268Jakafi $248Libtayo $246Enhertu $246Adcetris $245Opdualag $228Talzenna $225Padcev $211Mektovi $178Braftovi $178Ibrance $177Fruzaqla $170Orgovyx $167Krazati $159Pluvicto $157Brukinsa $155Elrexfio $153Lynparza $144Vitrakvi $141Stivarga $141Elahere $141Ultomiris $139Venclexta $133Imbruvica $132Lorbrena $131Inlyta $129Lutathera $112Lonsurf $110Inqovi $110Epkinly $108Tibsovo $106Besremi $101Rybrevant $98.88Orserdu $96.18Ojjaara $94.53Cosela $87.63Bosulif $86.01Erleada $82.77Trodelvy $80.47Vonjo $77.53Comirnaty $77.44Paxlovid $77.09Calquence $76.14Vyloy $75.76Nubeqa $73.66Zepzelca $71.48Xalkori $70.01Tecentriq $69.79Pyrukynd $66.77Yescarta $66.77Rolvedon $65.39Xospata $63.03Scemblix $60.70Welireg $56.83Pomalyst $56.72Fotivda $55.19Piqray $54.96Polivy $54.31Alunbrig $53.63Mozart $52.38Phesgo $49.88Perjeta $49.88Rytelo $47.89Fabhalta $46.04Darzalex $45.64Beleodaq $43.61Enjaymo $43.60Vanflyta $43.05Besponsa $42.55Talvey $41.84Verzenio $41.27Retevmo $41.27Jaypirca $41.27Lunsumio $39.84Zynyz $39.27Bavencio $37.14Monoferric $35.86Doptelet $34.91Lumakras $34.82Precisetumor $34.81Kcentra $32.08Jevtana $31.85Amtagvi $31.41Blincyto $31.14Kyprolis $31.14Quzyttir $30.69Injectafer $30.04Ayvakit $29.01Copiktra $28.39Itovebi $28.19Xofigo $27.87
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.